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Background: Accurate assessment of renal function in patients with cystic fibrosis (CF) is vital for determining the appropriate dose of
medications and for early detection of renal disease. Cystatin C (CysC) is a new marker of GFR with reportedly improved accuracy and precision
compared to methods incorporating serum creatinine. The purpose of this study is to evaluate the predictive performance of cystatin C in
estimating GFR in adult patients with CF.
Methods: Iothalamate was administered to enable measurement of GFR in 38 adult patients with CF and control subjects. Creatinine clearance
(C&G) and GFR estimates (cystatin C clearance [Cys C] and abbreviated modified diet in renal disease [aMDRD]) were compared using Bland–
Altman and receiver operating characteristic (ROC) analysis. GFR cutoff values of 80 and 90 mL/min–1.73 m2 were used in the analysis.
Results: The measured GFR was similar in both the CF and healthy volunteers 104 (32.2) and 105 (29.9), P=0.969 respectively. No significant
difference in mean bias was noted between the predictive methods within the CF population. Cys C provided the most precise estimates of GFR in
both populations. ROC curves demonstrated that CysC provided greater sensitivity and specificity compared to the aMDRD (AUC 0.93 vs. 0.54,
P=0.003) and C&G (AUC 0.93 vs. 0.56, P=0.005) in CF at a cutoff GFR of 90 mL/min–1.73 m2.
Conclusion: Cystatin C clearance provides an improved marker of glomerular filtration rate in CF patients.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Glomerular filtration rate; Cystatin C; Creatinine clearance; MDRD1. Introduction
An accurate assessment of renal function is vital to the dosing
and monitoring of drugs and for the early detection of renal
disease. This is of particular importance to patients with cystic
fibrosis who receive repeated courses of potentially nephrotoxic
antibiotics for the treatment of acute pulmonary exacerbations.
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doi:10.1016/j.jcf.2008.07.004renal failure (ARF) associated with intravenous aminoglycosides
is increasingly recognized in patients with CF [1,2].
The best index of renal function is glomerular filtration rate
(GFR). Iothalamate is considered a gold standard measure for
golumerular filtration rate (GFR) assessment, but requires in-
travenous infusion of the marker compound and timed urine
collections over several hours, making this an impractical meth-
od for routine clinical use [3].
The most commonly employed methods for quantifying
renal function in the clinical setting utilize the endogenous
biomarker, serum creatinine, to estimate the patient's glomer-
ular filtration rate. Creatinine is formed as a byproduct of mus-
cle catabolism at a relatively constant rate and is subsequently
excreted by the kidney providing a clinically useful marker ofd by Elsevier B.V. All rights reserved.
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creatinine is known to result in inaccurate estimations of renal
function in patients with malnutrition, liver disease, obesity, or
significant third spaced fluid [4]. In addition, certain foods rich in
creatine (e.g. red meat) and drugs that affect the tubular excretion
of creatinine (e.g. cimetidine) can alter serum creatinine con-
centrations independent of glomerular filtration [5]. Malnutrition,
which occurs as a consequence of pancreatic insufficiency and the
increased metabolic needs secondary to impaired respiratory
function, is a frequent complication of cystic fibrosis. A reduced
muscle mass in patients with CF may account for the over-
estimation of renal function utilizing methods incorporating se-
rum creatinine noted in a recent report [6].
An alternative endogenous biomarker to estimate GFR is
cystatin C, a cysteine proteinase inhibitor involved in the in-
tracellular catabolism of proteins. Structural analysis of the gene
and its promoter demonstrate that Cys C is constitutively ex-
pressed by all nucleated cells exhibiting a stable production rate
even in the presence of an acute inflammatory response [7]. It is
freely filtrated in the renal glomeruli and almost completely
reabsorbed and catabolized by the proximal tubular cells [8].
Studies performed in patients with various degrees of renal
function, liver disease, and spinal cord injuries have shown a
higher correlation and improved accuracy in predicting GFR
when compared with methods incorporating serum creatinine.
[9]. However, results in patients with diabetes, pediatric patients,
and those with early renal impairment did not show a significant
difference between Cys C and the formulas utilizing creatinine in
predicting GFR, indicating the performance may be patient
population specific [10–15]. Considering the malnutrition and
associated loss of muscle mass often observed in patients with
CF an evaluation of utility of cystatin C is warranted. Therefore,
the aim of this study was to compare the predictive performance
of Cys C clearance relative to existing methods for estimating
GFR in patients with CF and age-matched controls.
2. Methods
2.1. Study population and study design
Subjects were selected from two different open label ran-
domized studies evaluating the pharmacokinetics of diclox-
acillin and fexofenadine in cystic fibrosis (CF) patients compared
to healthy volunteers (HV) [16,17]. During these studies glo-
merular filtration rate (GFR) was measured using iothalamate as a
biomarker. Thirty-eight subjects, 19 cystic fibrosis (CF) patients
and 19 age-matched healthy volunteers, were included in the
present study. All CF patients had a confirmed diagnosis of cystic
fibrosis (positive sweat chloride test and/or known CF genotype).
None of the patients were currently pregnant or nursing an infant,
post solid organ transplantation, or had significant anemia, renal
or hepatic insufficiency. All subjects were older than 18 years and
within 70–130% of their ideal body weight. The study protocol
was approved by the Institutional ReviewBoard, and each subject
signed a written witnessed informed consent prior to participation
in the study. After completion of the informed consent each
subject participated in a screening visit, which included a reviewof medical history and physical examination (vitals, height, and
weight). Laboratory analysis included a completemetabolic panel
and complete blood count. All clinical work in both studies was
performed at the General Clinical Research Center (GCRC) at
LAC+USC Medical Center.
2.2. Study protocol
Subjects were admitted to the GCRC after an overnight fast.
A single dose of iothalamate meglumine 456 mg (Conray 30;
Mallinkrodt, St. Louis, MO) was administrated as an intrave-
nous push dose 1 h after an oral fluid load of 600 ml of caffeine-
free, sugar-free liquids. An oral fluid regimen was maintained at
150–200 ml/h for 6 h following the drug administration to
ensure sufficient hydration during the urine collection period.
Blood samples were drawn at times 0, 0.25, 0.5, 1, 2, and 3 h
after dosing for all subjects in both studies. Samples were kept
on ice until plasma was separated by centrifugation within
30 min of collection. Urine samples were obtained from spon-
taneous voiding every 30 min for the first 3 h after iothalamate
administration. Both urine and plasma samples were stored at
−70 °C until the time of analysis.
2.3. Determination of plasma and urinary iothalamate
concentrations
Iothalamate urine and plasma samples were analyzed based
on a previously published method [18]. Standard curves were
created by linear regression of peak area ratio of iothalamate to
theophylline (internal standard) versus known concentrations of
iothalamate. The plasma and urine standard curves were linear
in the range from 2–60 μg/ml and 10–250 μg/ml with cor-
relation coefficients of at least 0.99 and 0.98 respectively in the
first study and 0.94 and 0.99 respectively in the other. Unknown
samples were estimated by applying the equation of the linear
regression of the standard curve to the unknown sample peak
area. The inter-day coefficients of variation (CV) for plasma and
urine samples were less than 11% in both studies.
2.4. Pharmacokinetic analysis
Pharmacokinetic analysis was performed by applying a
1-compartmentmodel with first order elimination to themeasured
plasma and urinary concentrations of iothalamate using the
ADAPT II software (release 5, Biomedical SimulationsResource,
University of Southern California, Los Angeles). Analysis was
performed using the parametric expectation maximization
algorithm. The dose, plasma and urine iothalamate concentra-
tions, and the urine volumes were the inputs to the model.
Iothalamate clearance was modeled with renal and nonrenal
clearances. The primary output parameter of interest was the renal
clearance, which was used as the measured GFR for each subject.
2.5. Data analysis
Creatinine clearance was estimated using the method of Cock-
croft–Gault and normalized for body surface area.MeasuredGFR
Table 1
Subject demographics and clinical characteristics
CF (n=19) HV (n=19) P-values
Males/females 8/11 5/14 0.495
Age (years) 29.3 (7.17) 28.6 (6.48) 0.742
Weight (kg) 54.7 (6.24) 74.9 (15.9) b0.0001
Height (cm) 166 (8.06) 173 (11.0) 0.032
BMI (kg/m2) 20.3 (2.16) 24.8 (3.18) b0.0001
Serum creatinine (μmol/L) 65.4 (8.84) 82.2 (16.8) 0.001
Serum cystatin C (mg/L) 0.81 (0.15) 0.74 (0.09) 0.136
GFR (mL/min–1.73 m2) 104 (32.2) 105 (29.9) 0.969
Values are mean (standard deviation).
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normalized for body surface area. GFR was predicted using the
abbreviatedMDRD equation and cystatin C clearance. Cystatin C
clearance was estimated using the method of Tidman, where
GFR=100/CysC−14 [19].
2.6. Statistic analysis
Subject demographics and clinical characteristics were sum-
marized using descriptive statistics. Differences between CF
and healthy volunteers were determined using a two-tailed stu-
dent t-test or chi square test where appropriate. A p-value b0.05
was considered statistically significant. Methods described by
Bland and Altman [20] were used to evaluate the bias and
degree of agreement between the GFR estimates compared with
the measured GFR. The precision of the predictive methods was
determined from the standard deviation of the observed bias.
Accuracy was reported as the percent of values within 30% and
50% of the measured GFR. Pearson's correlation was used to
evaluate the relationship between body mass index (BMI) and
bias if present. Receiver operating characteristic (ROC) curves
described by Zweig and Campbell [21] were used to assess the
overall sensitivity and specificity of the estimation methods in
detecting a GFR of 80 and 90 mL/min–1.73 m2. In this method
the calculated sensitivity is plotted against 1-specificity for
different cutoff points. The area under the curve (AUC) is
indicative of the overall performance of the method and was
used to compare the different GFR estimation methods. AUC
values vary between 0.5 and 1.0. A useless test has a value of
0.5 and a perfect test has an area of 1.0. Cutoff values for GFR
were set at 90 mL/min and 80 mL/min for each population. TheTable 2
Bias, precision, and accuracy of GFR predictive equations
Mean (SD), mL/min–1.73 m2 Bias Precision P Ac
Cystic fibrosis
CLcr (C&G) 115 (23.1) 11.3 39.1 0.225 47.
GFR (aMDRD) 115 (22.5) 10.8 40.7 0.262 42.
GFR (CysC) 114 (20.4) 9.6 27.1 0.140 78.
Healthy volunteers
CLcr (C&G) 112 (17.0) 7.3 35.0 0.373 63.
GFR (aMDRD) 100 (16.3) − 4.3 31.7 0.561 79.
GFR (CysC) 124 (18.8) 19.4 27.5 0.007 68.
Values are mean (standard deviation).z-statistic was used to compare the area under the curve (AUC)
from each estimation method.
Statistical analyses were performed using Graphpad Prism
Version 5.0 for Macintosh, (Graphpad Software, San Diego Cali-
fornia USA) and MedCalc for Windows version 9.0 (MedCalc
Software, Mariakerke, Belgium).
3. Results
Demographic and clinical characteristics for the two groups
are presented in Table 1. Weight, height and body mass index
(BMI) were all significantly lower in the CF group. Serum
creatinine concentrations were also significantly lower in pa-
tients with CF when compared with the healthy volunteers.
These results are likely due to the difference in nutritional status
between the two groups. In contrast, no differences were noted
between the two groups in serum cystatin C or measured GFR.
The estimated values for GFR, the bias, precision, and ac-
curacy of the predictive equations are shown in Table 2 and
Fig. 1. No statistically significant within group differences were
noted in estimating the measured GFR with the exception of the
GFR predicted based on the cystatin C equation, which ap-
peared to overestimate the measured GFR in the healthy
volunteer group. The mean bias of the 3 predictive equations
was comparable in the patients with CF, whereas the MDRD
equation demonstrated the least bias in the healthy volunteer
group. No statistically significant correlation was found be-
tween BMI and the bias of cystatin C (Cys C) clearance (r=
0.233; P=0.160), C&G formula (r=0.085; P=0.612), or the
aMDRD formula (r=−0.163; P=0.327).
GFR estimates based on the Cys C equation appeared to
provide the greatest precision in both populations as indicated
by the least variability in bias (Table 2) and the most narrow
95% limit of agreement (LOA) in the Bland–Altman plots
(Fig. 1). Accuracy within 30% of the measured GFR was
greatest for the Cys C equation in the CF group, but no dif-
ferences were noted within 50% of the measured GFR. No
differences in accuracy of the predictive equations were ap-
parent in the HV group.
Five of the CF patients had CFRD; however, no statistically
significant difference was found between the predicted and
measured GFR values in these patients. In addition, the median
BMI for the patients with CFRD did not differ significantly
from the other CF patients (18.9 vs. 20.95 respectively).curacy % (within 30%) Accuracy % (within 50%) Relative difference (%)
4 84.2 21.1 (42.1)
1 89.5 21.6 (48.8)
9 84.2 16.1 (30.8)
2 79.0 16.3 (42.6)
0 89.5 3.2 (33.9)
4 79.0 25.6 (31.7)
Fig. 1. Bland and Altman plot for differences between estimated GFR and measured GFR in patients with CF (top panel) and healthy volunteers (bottom panel). On the
x-axis, the average GFR is given and on the y-axis the difference in mL/min-1.73 m2 between the estimated GFR, derived from the cys C formula (A), the MDRD
formula (B), or the C&G formula (C) is given. The mean difference (solid lines) and the 1.96 SD limits (dotted lines) are also plotted.
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ing the diagnostic accuracy for detection of an abnormal GFR
with the different formulas are shown in Fig. 2. Cutoff levels set
at 90 and 80 mL/min–1.73 m2 were chosen to define how
sensitive and specific the estimates of GFR were in identifying
mild reductions in GFR. ROC analysis was performed for CF
patients and healthy volunteers separately and is summarized in
Table 3. The AUC for Cys C was significantly greater than the
value for the C&GorMDRD in CF patients with a GFR cutoff of
90 mL/min–1.73 m2. The AUC for Cys C was also greater in CF
patients with a GFR cutoff of 80 mL/min–1.73 m2 but this did
not reach statistical significance. No significant difference in the
predictive equations was noted in the healthy volunteer group at
either GFR cutoff value.
4. Discussion
In this study, we demonstrate that cystatin C clearance may be
an alternative marker of GFR in patients with CF when com-
pared with estimates incorporating serum creatinine such as
C&G and an improved marker of GFR compared to the aMDRD
equation. Specifically, CysC demonstrated greater sensitivity
and specificity in identifying reduced GFRs (GFR cutoff value
of 90 mL/min–1.73 m2) when compared with the equations
incorporating serum creatinine in the cystic fibrosis population.
Prior studies comparing different methods of estimating
GFR in CF are few and none have been formally validated in
this population. Two studies are found in the literature com-
paring GFR methods in CF patients [6,22]. Touw et al. [22]
compared predicted and measured creatinine clearance in adult
patients [18] with CF. Results of this study showed that all threepredictors of creatinine clearance tended to over predict the
measured creatinine clearance. In a more recent study Al-Aloul
et al. compared measured 24-hour creatinine clearance with ten
different formulas used to predict GFR, including MDRD and
C&G in 74 adult CF patients and 29 matched normal controls
[6]. Seven of the formulas, including C&G and MDRD, were
found to be equally applicable in CF patients, and none dem-
onstrated superiority to the other in terms of precision of the
estimates or correlation with the measured creatinine clearance.
The authors concluded that the accuracy of these formulas is
limited and not as robust as the reference method (i.e. measured
creatinine clearance). The results of our study are in agreement
with these two studies demonstrating that the available
predictive methods appear to overestimate GFR in patients
with CF. Our results extend these findings to show that CysC
provides a more precise measure of GFR. In addition, CysC
provides greater sensitivity and specificity for identifying
reduced GFR.
To our knowledge, this is the first study to evaluate the new
biomarker Cys C in estimating GFR in patients with CF. In a
recent meta-analysis [9] serum cystatin C was determined to be
superior to serum creatinine (SCr) as a marker of kidney function
by both superior correlation coefficients and greater ROC-plot
AUC values in patients with various degrees of kidney function.
Additional studies performed in patients with various disease
states with clinical characteristics shared by patients with CF
(i.e. malnutrition, mild to moderate impaired kidney function,
diabetes) [5,23,24] are in agreement with these results sug-
gesting that the use of Cys C in CF patients may be favorable to
the formulas using serum creatinine. The results of the present
investigation suggest that Cys C is a suitable alternative marker
Fig. 2. ROC curve analysis of diagnostic accuracy of GFR estimated from cystatin C, MDRD, and C&G formulas in patients with CF (top panel) and healthy
volunteers (bottom panel). The GFR determined with iothalamate was used as the gold standard and the discrimination point was set at (A) GFR b90 mL/min-1.73 m2,
and (B) GFR b80 mL/min-1.73 m2.
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are several possible reasons for the apparent improved precision
and sensitivity/specificity of GFR estimates based on Cys C
rather than serum creatinine utilized in the aMDRD equation. In
contrast to serum creatinine, Cys C levels in the serum appear to
be unaffected by age, gender, weight, muscle mass, diet, or
physical activity [25]. A significantly higher correlation was
found between 1/Cys C and 51Cr-EDTA than with 1/Cr in spinal
cord injury patients [24]. In patients with liver cirrhosis, a
significantly greater correlation was found between 1/Cys C and
inulin compared to 1/Cr [26]. A poor correlation between GFR
and creatinine in individuals with muscle atrophy is likely a
result of reduced serum creatinine concentrations leading to a
falsely higher predicted GFR. Similarly, use of the aMDRD
equation for estimation of GFR in patients with malnutrition
resulted in significant overestimation of the measured GFR [4].
CF patients may also exhibit a reduced muscle mass due to
malnutrition as indicated by the significantly reduced BMI
noted in this population. While no significant correlation wasnoted between the bias of C&G or MDRD and the BMI, the
overall precision and in particular the sensitivity and specificity
in CF patients with GFR values 90 mL/min–1.73 m2 or above
were much improved with Cys C. Coll et al. [10], demonstrated
that serum creatinine levels only started to become abnormal
when the GFR was ~75 mL/min–1.73 m2. In contrast, elevated
values of Cys C were observed at a GFR of 88 mL/min–
1.73 m2. These results are supported by other studies [23,27] in
which ROC analysis revealed significantly larger AUCs for Cys
C when compared with creatinine in subjects with normal to
mild renal insufficiency. These results suggest that Cys C has an
improved diagnostic accuracy for identifying mild renal disease
and may perhaps provide earlier detection of renal impairment
in CF patients. This is of particular importance in patients re-
ceiving repeated intravenous aminoglycoside or colistimethate
courses for treatment of acute pulmonary exacerbations. In
addition, routine monitoring of Cys C may provide a more
sensitive marker of mild renal disease in patients with CFRD
allowing early intervention.
Table 3
ROC analysis for creatinine clearance (G&G), and GFR estimated cystatin C
clearance (CysC) and the abbreviatedMDRD equation in CF and healthy volunteers
GFR cutoff GFR estimate AUC 95% C.I. P-value
CF (n=19) 80 (n=14) C&G 0.543 0.303–0.769 0.092 a
Cystatin C 0.800 0.556–0.944 0.065 b
aMDRD 0.500 0.267–0.733 0.640 c
90 (n=10) C&G 0.556 0.314–0.779 0.005 a
Cystatin C 0.928 0.712–0.991 0.003 b
aMDRD 0.539 0.300–0.765 0.850 c
HV (n=19) 80 (n=16) C&G 0.646 0.397–0.847 0.517 a
Cystatin C 0.771 0.524–0.928 0.670 b
aMDRD 0.719 0.469–0.896 0.630 c
90 (n=14) C&G 0.686 0.436–0.874 0.830 a
Cystatin C 0.657 0.408–0.855 0.757 b
aMDRD 0.607 0.361–0.818 0.598 c
a CG vs. CysC.
b CysC vs. aMDRD.
c CG vs. aMDRD.
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GFR is altered in patients with CF demonstrating conflicting
results. Some showed a significantly increased GFR in the CF
population compared to controls [28–30], while others dem-
onstrate no significant differences [6,31–35]. A number of the
early studies conducted in the 1980s indicate GFR is higher in
patients with CF. In contrast, more recent studies starting in the
1990s demonstrate no significant differences in GFR. In par-
ticular, a study conducted by Strandvik et al. did not find any
significant difference in GFR between CF and healthy vol-
unteers. They suggested that the change from a fat-restricted
diet to a high fat diet in the late 1980s may be responsible for
normalization of the GFR in patients with CF and may account
for the apparent discrepancy in the studies [34]. The inves-
tigators tested their hypothesis in a clinical study in which they
provided fatty acid supplementation over a 3 year period. The
mean GFR decreased significantly from 133±19 mL/min–
1.73 m2 at the start of the study to 111±14 mL/min–1.73 m2
(Pb0.05) which was within normal values after 1-year [34].
Other possible reasons for the discrepancy in the published
studies of GFR may be related to differences in age or disease
severity. Our study results are consistent with those of recent
investigations and indicate no significant difference in GFR
between patients with CF and age-matched control subjects.
There are several limitations to our data. Firstly, the number
of subjects, although larger than most published studies with CF
to date, is small. In addition, the age range included adults
between the age of 20 and 44 years in HVand 24 to 48 years in
CF patients, but no adolescents or children. Age is one of the
determining factors for GFR, as GFR decreases significantly
when you get older. Taking this into account, subjects in our
study were age-matched and the GFR of iothalamate were not
significantly different between healthy volunteers and CF, but
additional studies in pediatric CF patients are needed. Finally,
subjects representing a full range of renal function were not
included in this study. Our primary interest was to characterize
GFR and renal clearance of drugs in representative patients with
CF and controls. Additional studies enrolling CF subjects with arange of renal function would help to determine the validity of
Cys C in patients with various degrees of renal function. Future
studies evaluating specific subgroups that have a higher risk for
renal disease, such as those with CFRD and those using mul-
tiple intravenous aminoglycoside courses would also be bene-
ficial in establishing the role of Cys C in CF.
In conclusion, we found Cys C clearance provides improved
sensitivity, specificity, and precision in estimating GFR in adult
patients with cystic fibrosis when compared with equations
incorporating serum creatinine (e.g., C&G and aMDRD). The
use of Cys C should be considered for clinical monitoring in the
CF population, particularly in those patients at higher risk for
renal disease, such as those with CFRD and those using multiple
intravenous aminoglycoside or colistimethate therapies.
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